Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05889013

Utility of PCD Diagnostics to Improve Clinical Care

This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).

Recruiting

Interested in participating?

Request Info

Key information

Age range

2 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This is an observational study to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). Participant selection will be on a referral basis for the consideration of a clinical suspicion for PCD. Participants will be identified by pulmonary providers that consider testing for PCD based on the clinical symptoms of the participant. These providers will then refer for enrollment in the study based on the clinical considerations for a diagnosis of PCD. Participants will be consented during the time of testing at the Pulmonary department. Any patient referred by a clinician for concerns for PCD, including those who have had PCD genetics sent, or a ciliary biopsy performed will be enrolled in the study. In addition, any participant who is referred for nasal nitric oxide testing and meets the inclusion and exclusion criteria for this testing, will also need to provide informed consent and be enrolled in the Nasal NO REDCap registry. This equipment is not currently FDA approved or CLIA certified for PCD diagnostic testing and therefore referring clinicians will be informed that the results of this test should not influence clinical decision making regarding the diagnosis of PCD. However, there is growing evidence that this testing has utility as a non-invasive screening tool for PCD and continued data from the general pediatric pulmonary population is needed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 2 years of age
  • Must have two of the following clinical history points:
  • Neonatal respiratory distress
  • Chronic nasal congestion/runny nose
  • Chronic cough
  • Situs/laterality defects
  • Bronchiectasis
  • Ability to provide informed consent or consent of parent/guardian and ass

Exclusion criteria

  • Recent history of sinus surgery or bloody nose in the past week
  • Age < 2 years of age
  • Inability to tolerate probe in nose
  • Sinusitis or other respiratory exacerbation currently being treated with antibiotics
  • Admitted to hospital for respiratory exacerbation (inpatient status)
  • Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by the IRB)
  • Any other reason for which the study investigators feel the patient is not a good candidate to complete the testing

Treatment and study plan

Nasal Nitric Oxide testing

Device

Collection of already performed clinical data and nNO testing

Other names: nNO testing

Primary outcomes

  1. Creation of Nasal NO REDCap registry

    Time frame: 2-3 years

    To establish a research registry to characterize the features of individuals that undergo PCD diagnostic testing at Connecticut Children's Medical Center and UCONN.

  2. Evaluation of utility of PCD diagnostic testing

    Time frame: 2-3 years

    To evaluate the utility of PCD diagnostic testing, including potential use of nasal nitric oxide in comparison to genetic testing and ciliary biopsy, in pulmonary practice at Connecticut Children's Medical Center and UCONN.

Secondary outcomes

  1. Refinement and Improvement of PCD Diagnostic Testing

    Time frame: 1-2 years

    To refine and improve current diagnostic processes for PCD diagnosis at CCMC using information gathered from the research registry established through Primary aims 1 and 2.

Study contacts

Contact information is provided by the study sponsor or research team.

Melanie S Collins, MD

CONTACT

[email protected]

860-545-9440

Sigrid M Almeida, BS

CONTACT

[email protected]

8608375343

Sponsors and collaborators

Lead sponsor

Connecticut Children's Medical Center

Other

Collaborators

  • UConn Health

Registry information

Official study title

A Clinical Study to Gather Data on the Utility of Tests That Are Used to Make a Diagnosis of Primary Ciliary Dyskinesia (PCD)

Acronym: PCD

Important dates

Study start
2023
Primary completion
2027
Study completion
2028
First posted
Jun 5, 2023
Registry last updated
Sep 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.